HEALTH-CORONAVIRUS-BIOMERIEUX: BioMerieux is developing three new diagnostic tests for coronavirus
PARIS (Reuters) – The pharmaceutical group bioMerieux announced on Wednesday the coming launch of three tests aimed at responding to the coronavirus epidemic.
The development of a first SARS-CoV-2 R-GENE test in real time has been finalized and validated and will be available from the end of March, the group said in a press release. It should quickly benefit from a European Commission marking and will be the subject of an application for authorization of emergency use to the FDA, the American drug agency.
A new fully automated test is under development with the support of the United States Department of Defense.
Finally, bioMerieux is developing a new version of an existing test. This new panel, writes the group, will integrate SARS-CoV-2 in addition to the 21 pathogens most frequently responsible for respiratory infections that it already allows to detect, in about 45 minutes.
These two tests will be submitted to regulatory authorities in the second and third quarters.
“Faced with the urgency of the Covid-19 epidemic, bioMerieux is committed to offering a complete diagnostic solution that meets the highest performance and quality requirements, in order to help clinicians effectively fight against this epidemic, “said Dr. Mark Miller, executive director for medical affairs at bioMerieux.